Barry Greene, Sage CEO

Sage touts first win in $3B Bio­gen pact, but safe­ty pro­file, doubts over da­ta cloud road ahead

The big test is still weeks or months away, but Sage and Bio­gen have scored their first, al­beit nar­row, win since sign­ing their $3.1 bil­lion deal last year.

The biotechs an­nounced Mon­day that SAGE-324, the sec­ond ma­jor mol­e­cule in the pact, had cleared a Phase II tri­al for es­sen­tial tremor, a pro­gres­sive dis­or­der that caus­es in­vol­un­tary mus­cle move­ment in about 6.4 mil­lion Amer­i­cans. Pa­tients in the 67-per­son study who re­ceived the drug had a 36% re­duc­tion of up­per limb tremor on a stan­dard med­ical scale, com­pared to a 21% re­duc­tion for pa­tients on place­bo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.